Loading organizations...
Harbour Biomed has raised $263.0M across 4 funding rounds.
Key people at Harbour Biomed.
Harbour Biomed has raised $263.0M in total across 4 funding rounds.
Harbour BioMed is a global biopharmaceutical company focused on the discovery, development, and commercialization of novel antibody therapeutics in oncology and immunology, with operations in Cambridge, MA, Rotterdam, Suzhou, and Shanghai. The company builds its pipeline through internal R&D, collaborations, and partnerships, leveraging subsidiaries like Harbour Therapeutics and Nona Biosciences for clinical-stage assets and technology platforms. It has secured substantial funding, including a $102.8 million Series C round in 2022 led by Hudson Bay Capital, a $75 million Series B+ in March 2020, and an initial $50 million financing in 2016. Other key investors include OrbiMed, Advantech Capital, and Legend Capital, while partners include NK Cell-Tech and Élancé Therapeutics. Harbour BioMed is publicly listed on the HKEX (02142). The company was founded in 2016 by Jingsong Wang.
Harbour BioMed is a global biopharmaceutical company focused on discovering, developing, and commercializing novel antibody therapeutics, primarily in oncology and immunology.[1][2][5] It builds proprietary technology platforms like Harbour Mice® for generating fully human monoclonal antibodies in H2L2 and HCAb formats, HBICE® for immune cell engagers targeting tumors, and single B cell cloning integrated with AI tools such as the Hu-mAtrIx™ generative AI HCAb model.[1][2][3] These platforms serve pharmaceutical partners, academic institutions, and its own pipeline, solving unmet needs in antibody discovery by accelerating lead generation to ~4 months (vs. industry 9 months), enabling bispecifics, and improving developability for next-gen biologics.[1][3] The company operates through Harbour Therapeutics for internal assets and Nona Biosciences for open-access tech licensing, with a portfolio including 5 clinical-stage compounds, over 200 preclinical candidates, and at least 6 antibodies in human trials from its platforms.[2][5][6] Growth momentum includes recent AI launches and partnerships with over 40 entities, driving "Healthy life · Breakthrough Medicines."[2][5]
Harbour BioMed was established in 2016, building a robust pipeline in oncology and immunology from the start.[4][6] It leverages exclusive global rights to Harbour Mice® platforms, engineered for high-quality, diverse fully human antibodies via in vivo maturation.[1][5] Key evolution includes acquiring Berkeley Lights’ Beacon® optofluidic tech in early 2019 for single B cell cloning, enhancing discovery efficiency, and launching business units like Nona Biosciences for tech access.[1][2][4] Pivotal moments feature partnerships with global academics and pharmas, co-developments like biosimilars (e.g., Binocrit®, bevacizumab), and clinical assets such as anti-IP10 antibody Eldelumab, yielding 5 in-licensed clinical compounds and rapid internal NextGen projects.[2][5] By 2025, it introduced the first fully human generative AI HCAb model, marking a shift to AI-driven innovation.[3]
Harbour BioMed rides the next-gen biologics wave, emphasizing AI-augmented antibody discovery amid rising demand for oncology/immunology therapies where traditional methods fall short on speed and specificity.[3][5] Timing aligns with AI-biotech convergence (e.g., 2025 HCAb model launch) and bispecific/multi-specific boom, fueled by market forces like patent cliffs on blockbusters and need for tumor microenvironment engagers.[1][2][3] It influences the ecosystem by licensing platforms to 40+ companies/academics, accelerating 200+ candidates to preclinical/clinical stages, and bridging China-global innovation via HKEX listing (02142) and sites in Shanghai, Rotterdam, Cambridge.[2][5] This democratizes high-quality human antibodies, reducing reliance on murine models and boosting efficiency in a $200B+ biologics market.
Harbour BioMed is poised to lead AI-powered antibody innovation, with its self-evolving platforms driving more clinical wins from its 200+ preclinical pool and expanding HBICE®/HBICA™ applications.[3][5] Trends like generative AI in drug design, cross-species binders, and multi-specifics will shape its path, potentially yielding breakthrough approvals in hard-to-treat cancers/inflammations. Influence may evolve via deeper pharmas partnerships and Nona's open model, amplifying global access while Harbour Therapeutics advances internal assets—positioning it as a transformative force from discovery to "Healthy life · Breakthrough Medicines."[2]
Harbour Biomed has raised $263.0M across 4 funding rounds. Most recently, it raised $100.0M Series C in July 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2020 | $100M Series C | JO WEN LIN | OrbiMed, AEF Greater BAY Area Fund, Country Garden Venture Capital, Gtja Investment Group, Octagon Capital, Sage Partners | Announced |
| Mar 12, 2020 | $75M Series B | — | Advantech, Efung Capital, GIC, Greater BAY Area Homeland Development Fund, JT NEW Century, Legend Capital, SK, Zhejiang University Future Capital | Announced |
| Aug 27, 2018 | $85M Series B | GIC | Advantech, Legend Capital, Vertex Ventures | Announced |
| Jul 1, 2013 | $3M Series A | — | Atlas Venture | Announced |
Key people at Harbour Biomed.
Harbour Biomed has raised $263.0M in total across 4 funding rounds.
Harbour Biomed's investors include Jo-Wen Lin, OrbiMed, AEF Greater Bay Area Fund, Country Garden Venture Capital, GTJA Investment Group, Octagon Capital, Sage Partners, AdvanTech, Efung Capital, GIC, Greater Bay Area Homeland Development Fund, JT New Century.
